1. Home
  2. BHC vs ADMA Comparison

BHC vs ADMA Comparison

Compare BHC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bausch Health Companies Inc.

BHC

Bausch Health Companies Inc.

HOLD

Current Price

$5.81

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$9.81

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHC
ADMA
Founded
N/A
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
BHC
ADMA
Price
$5.81
$9.81
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$8.00
$25.67
AVG Volume (30 Days)
2.0M
2.0M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
423.08
N/A
EPS
N/A
0.35
Revenue
$8,724,000,000.00
$42,219,783.00
Revenue This Year
$4.61
$27.46
Revenue Next Year
N/A
$22.11
P/E Ratio
N/A
$27.16
Revenue Growth
N/A
43.85
52 Week Low
$4.33
$7.21
52 Week High
$8.00
$20.46

Technical Indicators

Market Signals
Indicator
BHC
ADMA
Relative Strength Index (RSI) 39.53 58.53
Support Level $5.42 $9.23
Resistance Level $5.96 $10.24
Average True Range (ATR) 0.24 0.30
MACD -0.10 0.01
Stochastic Oscillator 9.76 98.34

Price Performance

Historical Comparison
BHC
ADMA

About BHC Bausch Health Companies Inc.

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: